TY  - JOUR

T1  - Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

JO  - Health Technol Assess

PY  - 2004/09/01

AU  - Knight C

AU  - Hind D

AU  - Brewer N

AU  - Abbott V

ED  - 

DO  - DOI: 10.3310/hta8370

VL  - 8

IS  - 37

SP  - iii

EP  - 82

Y2  - 2024/10/22

ER  -